Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Time to Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up prior to trading on Monday . The stock had previously closed at $45.49, but opened at $48.89. Nanobiotix shares last traded at $48.6450, with a volume of 18,740 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NBTX. UBS Group raised their target price on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Guggenheim lifted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Finally, TD Cowen restated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Trading Up 17.0%

The business has a fifty day moving average of $32.58 and a 200-day moving average of $25.53.

Nanobiotix (NASDAQ:NBTX) last released its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $3.42 million during the quarter. Analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current year.

Institutional Investors Weigh In On Nanobiotix

A number of institutional investors have recently bought and sold shares of NBTX. Millennium Management LLC acquired a new stake in shares of Nanobiotix during the 4th quarter valued at about $390,000. Royal Bank of Canada lifted its holdings in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Nanobiotix during the 4th quarter valued at about $220,000. Finally, Optiver Holding B.V. acquired a new stake in shares of Nanobiotix during the 3rd quarter valued at about $101,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.